HOME >> MEDICINE >> NEWS
Mayo Clinic: New recommendations for use of bisphosphonates in treatment of multiple myeloma

ROCHESTER, Minn. -- Mayo Clinic's multiple myeloma (MM) research team has jointly issued a consensus statement regarding the use of bisphosphonates to prevent or treat bone disease in MM. Their recommendations address several controversial issues, including the type of bisphosphonate to be used and the duration of such therapy, and are available in the August issue of Mayo Clinic Proceedings.

"It was imperative that we address the issue that has been under recent intense debate due to patient safety concerns," said Martha Lacy, M.D., Mayo Clinic hematologist and lead author of the statement. "These drugs have far-ranging effects that raised concerns in the medical field, so we brought together the relevant specialists to develop a set of best practice recommendations. We published them in Mayo Clinic Proceedings in order to provide other physicians the benefit of our shared knowledge."

The Mayo Clinic team provided recommendations for the myeloma patients for whom bisphosphonates are indicated. They said pamidronate should be the bisphosphonate of choice for patients who are starting therapy, over the newer, more potent drug zoledronic acid, which is more frequently associated with serious damage to jaw bones. Also in the interest of safety, the team recommended that patients without active disease stop bisphosphonate therapy after two years, and patients with active disease reduce the frequency at which the drugs are given.

MM is a malignant plasma cell disorder that is diagnosed in more than 15,000 people each year in the United States, and which causes more than 11,000 deaths. There are a variety of treatment options for MM, but it remains an incurable disease with current emphasis placed on enhancing quality of life while the cure is sought.

Because bone destruction causes significant problems for MM patients, and painful results include osteoporosis, lytic bone disease and skeletal fractures, clinicians seek t
'"/>


10-Aug-2006


Page: 1 2

Related medicine news :

1. Mayo Clinic: Sinusitis is common yet often overlooked cause of chronic cough
2. Mayo Clinic: Biomarker that may improve quality of life during treatment for colorectal cancer
3. Article outlines current recommendations for treating malaria in the US
4. Drug safety recommendations lack scientific evidence
5. SCAI issues recommendations to prevent kidney damage after imaging procedures
6. New recommendations for the diagnosis of Pulmonary Embolism
7. Latest influenza science and recommendations presented in new release
8. Heart Rhythm Society publishes final recommendations for heart patients
9. UK recommendations on the availability of common painkillers are being contravened
10. NIDA announces recommendations to treat drug abusers, save money and reduce crime
11. Concern over aggressive cholesterol recommendations

Post Your Comments:
(Date:12/19/2014)... 19, 2014 B. E. Smith, the ... providers, has been retained to lead a national ... Center in Estes Park, Colo. The top executive search ... recently placed more than 900 healthcare executives into organizations. ... 25-bed, not-for-profit critical access hospital and level IV trauma ...
(Date:12/19/2014)... TX (PRWEB) December 19, 2014 ... a shifting, capital equipment market that is saturated ... impressive safety and efficacy as well as non-invasive ... they were first introduced to the healthcare market. ... the development of MRI safe technologies have greatly ...
(Date:12/19/2014)... 19, 2014 Hands On Mobile Spa, has ... The Spa On Wheels has been transformed into a utopia ... outside world seems to disappear. The Virtual Tour showcases the ... spa parties, corporate events and more. , The Virtual Tour ... Wheels which is actually an overhauled Winnebago. Marla Kaplan-Pelle, Director ...
(Date:12/19/2014)... If you have ever been unable to ... wished you had an arsenal of treatments to battle ... other breathing disorders. Currently, the only proven methods for ... other common treatments do exist. At the recent ... TX, 34 asthma educators responded to a Harmonica Techs ...
(Date:12/19/2014)... Slone Partners , a national recruitment firm ... and laboratory testing industries, has promoted Leslie Loveless ... announcement comes after a year of expansion by ... Boston and several new additions to the team. ... experience," said Adam Slone, Chief Executive Officer. “Diagnostics ...
Breaking Medicine News(10 mins):Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2
(Date:12/19/2014)... 18, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year 2015 results on Thursday, January 22, 2015, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:12/19/2014)... CITY, Kan. , Dec. 18, 2014 /PRNewswire/ ... PETX ), a biopharmaceutical company focused on the ... companion animals, today announced positive results from its ... innovative drug for treating pain in dogs with ... improvements in pain assessment scores that were statistically ...
(Date:12/17/2014)... and SAN DIEGO , Dec. ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... measurement solutions for cardiovascular applications, today announced that they have ... Philips will commence a tender offer to acquire all of ... per share, or a total equity purchase price of USD ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
Cached News: